Evropska unija - slovenščina - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - multiplo sklerozo, recidivno-nakazila - imunosupresivi - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - multiplo sklerozo, recidivno-nakazila - imunosupresivi, selektivno imunosupresivi - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - multiple skleroza - selektivni imunosupresivi - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teriflunomid - filmsko obložena tableta - teriflunomid 14 mg / 1 tableta

Evropska unija - slovenščina - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - multiplo sklerozo, recidivno-nakazila - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.

Evropska unija - slovenščina - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fingolimod - kapsula, trda - fingolimod 0,5 mg / 1 kapsula - fingolimod

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fingolimod - kapsula, trda - fingolimod 0,5 mg / 1 kapsula - fingolimod

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fingolimod - kapsula, trda - fingolimod 0,5 mg / 1 kapsula - fingolimod

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fingolimod - kapsula, trda - fingolimod 0,5 mg / 1 kapsula - fingolimod